Feature | May 12, 2014

Remote Patient Management Study Demonstrates Significant Reduction in Mortality and Hospitalization

PREDICt-RM collaborative study highlights improved outcomes in ICD and CRT-D patients followed with Latitude system

May 12, 2014 — Patients using the Boston Scientific Latitude remote patient management system with wireless telemetry demonstrated significantly lower mortality and fewer hospitalizations than patients with Latitude-compatible devices who were not followed on the system, according to results from the PREDICt-RM study (Patient RElated Determinants of ICD Remote Monitoring Utilization and Outcomes). The results were presented at Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

PREDICt-RM demonstrated a 33 percent relative reduction in the risk of death in patients with Boston Scientific ICDs (implantable cardioverter-defibrillators) and CRT-Ds (cardiac resynchronization therapy devices) who were remotely monitored via Latitude, compared to patients who were not remotely monitored. Additionally, these patients experienced a 19 percent relative reduction in hospitalizations for any cause. The study outcomes were presented by Joseph Akar, M.D., Ph.D., associate professor of medicine at Yale University and the Center for Outcomes Research and Evaluation (CORE) in New Haven, Conn., and are a result of collaboration between Yale CORE, the American College of Cardiology (ACC) and Boston Scientific.

"The PREDICt-RM results demonstrate improved outcomes for those ICD and CRT-D patients using the Latitude wireless remote patient management system," said Akar. "Despite the widespread availability of this technology, we know that it is underutilized. Our hope is that this study may inform clinical practice guidelines and promote the routine use of this technology in daily practice."

PREDICt-RM’s results were made possible via a unique research design that linked three large healthcare databases, illuminating the potential for "big data" and healthcare analytics to advance patient care. PREDICt-RM combined the National Cardiovascular Data Registry (NCDR) from ACC, CMS data from Medicare, and the Boston Scientific Latitude system. 

"No single database could have answered this question effectively. Through an innovative collaboration with ACC and Boston Scientific, we were able to leverage the strengths of each database to develop a deeper understanding of the association of remote monitoring with patient outcomes. We believe the PREDICt-RM experience should serve as a model for this type of investigation," said Jeptha Curtis, M.D., associate professor of medicine at Yale University and CORE.

"PREDICt-RM demonstrates that wireless remote monitoring using the Latitude system provides a significant benefit to patients and the overall healthcare system," said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific. "We are very excited to have such strong data demonstrating substantially improved survival and reduced hospitalization rates in the patients followed on Latitude."

The Latitude remote patient management system connects a home communicator to the patient's implanted Boston Scientific device through wireless telemetry, enabling automatic collection of patient data. The system capabilities include transmitting physiologic data, as well as data gathered from the implanted device to the healthcare team's Latitude website. The Latitude system is the only implanted-device monitoring system with integrated physiologic monitoring of weight and blood pressure in the United States.

For more information: www.bostonscientific.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init